Clinical-Stage Companies / Quince

Quince

Pre-Approval PRO BETA

🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 12/11/2024

Total Trials

Phase 3

Phase 2

Recruiting

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Ataxia Telangiectasia Genetic Syndrome Healthy Nervous System Disorder Crohn's Disease

Clinical Trials (8)

NCT06664853 Phase 3 TERMINATED

Open-Label Extension of EryDex Study IEDAT-04-2022

Started: 12/11/2024

NCT06193200 Phase 3 COMPLETED

Evaluate the Neurological Effects of EryDex on Subjects With A-T

Started: 6/24/2024

NCT03563053 Phase 3 TERMINATED

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

Started: 6/12/2018

NCT01277289 Phase 3 TERMINATED

Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

Started: 6/3/2009

NCT02770807 Phase 3 COMPLETED

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Started: 3/2/2017

NCT01255358 Phase 2 COMPLETED

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Started: 2/1/2011

NCT02380924 Phase 1 COMPLETED

Recovery and Survival of EryDex in Non-patient Volunteers

Started: 1/1/2015

NCT01925859 Phase 1 COMPLETED

EryDex Pharmacokinetics in Healthy Volunteers

Started: 6/1/2013

Drug Candidates

Dexamethasone sodium phosphate EryDex Low dose DSP EryDex High dose DSP DSP loaded RBC using EryDex System EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)

Activity Status: Slowing

Last Trial Started: 12/11/2024

Last Trial Ended: 1/30/2026

Trials (12 months): 0

Completed Trials: 5

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.